Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]MK-6240 PET Imaging in Alzheimer's Disease
NCT03071224Phase 1Completed
- Sponsor
- Invicro
- Start
- Jun 2016
- Primary completion
- Jun 2021
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of florquinitau in Alzheimer's disease (AD), sponsored by Invicro. Primary endpoint: Longitudinal change in tau burden at 1 year. Started Jun 2016; status: completed.
02
Drugs
florquinitau
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03071224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03071224.